Braveheart Bio, Inc. (BRVE)

Braveheart Bio Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025
Period Ending	Mar 31, 2026	Dec 31, 2025
Cash & Equivalents	80.58	89.16
Cash & Short-Term Investments	80.58	89.16
Cash Growth	-	-
Prepaid Expenses	0.5	0.12
Total Current Assets	81.07	89.28
Other Long-Term Assets	0.07	0.07
Total Assets	81.88	89.35

Liabilities

Fiscal Year	TTM	FY 2025
Period Ending	Mar 31, 2026	Dec 31, 2025
Accounts Payable	7.74	1.06
Accrued Expenses	1.89	1.18
Other Current Liabilities	-	3
Total Current Liabilities	10	5.24
Other Long-Term Liabilities	0.09	0.09
Total Liabilities	10.39	5.33

Shareholders' Equity

Fiscal Year	TTM	FY 2025
Period Ending	Mar 31, 2026	Dec 31, 2025
Common Stock	0	0
Additional Paid-In Capital	1.94	0.18
Retained Earnings	-80.33	-66.05
Total Common Equity	-78.39	-65.87
Shareholders' Equity	71.49	84.02
Total Liabilities & Equity	81.88	89.35

Additional Metrics

Fiscal Year	TTM	FY 2025
Period Ending	Mar 31, 2026	Dec 31, 2025
Net Cash (Debt)	79.91	89.16
Net Cash Growth	-	-
Net Cash Per Share	2.62	5.30
Filing Date Shares Outstanding	30.48	29.28
Total Common Shares Outstanding	30.48	29.28
Working Capital	71.07	84.04
Book Value Per Share	-2.57	-2.25
Tangible Book Value	-78.39	-65.87
Tangible Book Value Per Share	-2.57	-2.25

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 31, 2026

Data Sources Report a data error